Germany - Drugs

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedural designation "open procedure" (Section IV.1.1) used in the text of this announcement is due to the requirements of the announcement form. Neither this nor the use of the "TED" medium is associated with any submission to procurement law regulations, the application of which is not mandatory by virtue of the law or procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The contract covers drugs containing the active ingredient combination abacavir and lamivudine and zidovudine. The subject of the agreement are drugs containing the active ingredient albendazole. The subject of the Agreement are medicinal products containing the active ingredient combination doravirine and lamivudine and tenofovir disoproxil. The subject of the Agreement are medicinal products containing the active ingredient etravirine. The subject of the Agreement are medicinal products containing the active ingredient filgrastim. The subject of the agreement are medicinal products containing the active ingredient fosamprenavir. The subject of the Agreement are medicinal products containing the active ingredient haloperidol in a parenteral, non-retarded dosage form or as an oral solution. The subject of the Agreement are medicinal products containing the active ingredient isosorbide dinitrate. The subject of the Agreement are medicinal products containing the active ingredient lacosamide. The Contractual Products are medicinal products containing the active ingredient levofloxacin in a parenteral dosage form. The subject of the Agreement are medicinal products containing the active ingredient methocarbamol in an active strength of 1500 mg. The subject of the Agreement are medicinal products containing the active ingredient pantoprazole in a parenteral dosage form. The subject of the Agreement are medicinal products containing the active ingredient PEG-epoetin beta. The subject of the Agreement are drugs containing the active ingredient pegfilgrastim. The subject of the Agreement are drugs containing the active ingredient peginterferon alfa-2a. The subject of the Agreement are drugs containing the active ingredient pegvisomant. The subject of the Agreement are drugs containing the active ingredient pimecrolimus. The contract covers drugs containing the active ingredient sitagliptin. The Contractual Products are medicinal products containing the active ingredient combination sitagliptin and metformin. The Contractual Products are medicinal products containing the active ingredient trastuzumab at 600 mg. The contract goods are individually manufactured parenteral preparations of finished medicinal products, which have been manufactured from the drug trastuzumab with an active strength of 150 mg. The subject of the agreement are medicinal products containing the active ingredient vedolizumab.

Opportunity closing date

01 September 2024

Value of contract

£0-100k